跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT03773666
NCT03773666已完成1 期

A Feasibility Study of Durvalumab (MEDI4736) Alone or in Combination With Oleclumab (MEDI9447) as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)

Dana-Farber Cancer Institute2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2019年2月20日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
12
试验地点
2
主要终点
Number of Participants Receiving at least One Dose of Study Therapy Followed by Surgery without Dose-Limiting Toxicity (DLT) up to Twelve Weeks Post-Radical Cystectomy (RC)
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This research study is studying a new anti-cancer drug durvalumab (MEDI4736) with or without another new anti-cancer drug Oleclumab (MEDI9447) before surgery for bladder cancer.

The drugs involved in this study are:

  • Durvalumab (MEDI4736)
  • Oleclumab (MEDI9447)

详细描述

This research study is a Feasibility Study, which is the first time investigators are examining these drugs, Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in patients with muscle-invasive bladder cancer (MIBC) cancer prior to surgery. Cisplatin-containing chemotherapy given before surgery is the standard of care in patients with MIBC because it increases the rate of cure after surgery. Participants may still be eligible for this study if their doctor determines that participants are able to receive cisplatin-containing chemotherapy, but the participants elect not to undergo chemotherapy before surgery, understanding the potential benefits of chemotherapy. The FDA (the U.S. Food and Drug Administration) has not approved Durvalumab (MEDI4736) for localized bladder cancer prior to surgery, but it has been approved for other uses, including for locally advanced or metastatic bladder cancer after progression on platinum-containing chemotherapy. The FDA (the U.S. Food and Drug Administration) has not approved Oleclumab (MEDI9447) as a treatment for any disease. Durvalumab is a monoclonal antibody (an antibody is a protein produced by the body's immune system) that works by blocking the Programmed Cell Death Ligand 1 (PD-L1), a protein on cancer cells that stops the body's immune system from killing cancer cells, to increase the body's immune response to prevent or slow down cancer growth. Oleclumab is a monoclonal antibody that works by reducing the amount of adenosine, a small molecule called a metabolite that binds to adenosine receptors on immune cells to regulate the immune system and suppress the immune response. Reducing the amount of immunosuppressive adenosine can increase the body's immune response to kill cancer cells. It is hoped that by combining Oleclumab with Durvalumab, an even greater immune response against the tumor will be generated. This research study is designed to see if the new anti-cancer drug Durvalumab (MEDI4736) with or without another new anti-cancer drug Oleclumab (MEDI9447) can be safely administered before surgery for bladder cancer

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • •For inclusion in the study patients must fulfil all of the following criteria: Written informed consent and any locally-required authorization (e.g. HIPAA) obtained from the patient prior to performing any protocol-related procedures, including screening evaluations
  • •Age > 18 years at time of study entry
  • •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (See Appendix A).
  • •Histologically confirmed bladder transitional cell carcinoma (TCC)
  • •--Patients with mixed histology are required to have a component of TCC, and no component of small cell histology
  • •T2-T4a N0 M0 disease, considered appropriate and planned for radical cystectomy
  • •Ineligible for cisplatin-based chemotherapy, defined by any of the following:
  • •Creatinine clearance (CL) <60 mL/min. GFR should be calculated from serum/plasma creatinine using the Cockcroft-gault formula.
  • •CTCAE v5.0 Grade > 1 hearing loss
  • •CTCAE v5.0 Grade > 1 neuropathy
  • •NYHA Class > II cardiac dysfunction
  • •Patients not meeting the above criteria are eligible if she/he declines perioperative cisplatin-based chemotherapy after specific informed consent describing the known benefits of cisplatin-based chemotherapy.
  • •Adequate organ function laboratory values as defined below:
  • •Hemoglobin ≥ 9.0 g/dL
  • •Absolute neutrophil count (ANC) 1.5 x (> 1500 per mm3)
  • •Platelet count ≥100 x 109/L (>75,000 per mm3)
  • •Albumin > 2.5 g/dL
  • •International Normalized Ratio (INR) or activated partial thromboplastin time (aPTT) < 1.5 x ULN, unless the patient is receiving anticoagulation therapy provided INR or PTT is within the therapeutic range of the intended anticoagulant therapy.
  • •Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN)
  • •--This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.
  • •AST (SGOT)/ALT (SGPT) ≤2.5 x institutional upper limit of normal
  • •Measured creatinine CL >30 mL/min or Calculated creatinine CL>30 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance:
  • •Creatinine CL (mL/min) = Weight (kg) x (140 - Age) 72 x serum creatinine (mg/dL)
  • •Creatinine CL (mL/min) = Weight (kg) x (140 - Age) x 0.85 72 x serum creatinine (mg/dL)
  • •Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
  • •Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the postmenopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
  • •Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiationinduced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).
  • •Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
  • •Availability of baseline archival tumor tissue obtained for correlative studies dated within 8 weeks of study registration.
  • •Either FFPE tumor tissue block or a minimum of fifteen 5μm unstained FFPE slides and fifteen 10μm unstained FFPE slides with an associated pathology report is required.
  • •Patients without adequate baseline tumor tissue or have archival tumor tissue >8 weeks from registration must undergo cystoscopic tumor biopsy, meeting the above tissue criteria.

排除标准

  • •Patients with primary TCC of the ureter, urethra, or renal pelvis without TCC of the bladder
  • •Inoperable tumor(s) with fixation to the pelvic wall on clinical exam
  • •Any previous systemic chemotherapy or radiotherapy for TCC of bladder
  • •Participation in another clinical study with an investigational product during the last 6 months
  • •Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study
  • •Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab
  • •History of another primary malignancy except for:
  • •Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of study drug and of low potential risk for recurrence
  • •Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
  • •Adequately treated carcinoma in situ without evidence of disease (e.g. cervical cancer in situ)
  • •Receipt of the last dose of intravesical chemotherapy or biologic therapy
  • •≤ 42 days (6 weeks) prior to the first dose of study drug for patients who have received prior intravesical chemotherapy or biologic therapy (e.g. BCG)
  • •Mean QT interval corrected for heart rate using Fridericia's formula (QTcF)
  • •≥470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart) for durvalumab + oleclumab cohorts only. Patient safety and the cardiac EKG should be consulted as needed.
  • •Any unresolved toxicity NCI CTCAE version 5.0 Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria
  • •Patients with Grade ≥2 neuropathy will be evaluated on a case-bycase basis after consultation with the Study Physician.
  • •Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab and/or oleclumab may be included only after consultation with the Study Physician.
  • •Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g. hormone replacement therapy) is acceptable.
  • •Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.
  • •History of allogenic organ transplantation
  • •Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g. colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:
  • •Patients with vitiligo or alopecia
  • •Patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on hormone replacement
  • •Any chronic skin condition that does not require systemic therapy
  • •Patients without active disease in the last 5 years may be included but only after consultation with the study physician
  • •Patients with celiac disease controlled by diet alone
  • •Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
  • •History of leptomeningeal carcinomatosis
  • •Brain metastases or spinal cord compression. Patients with suspected brain metastases at screening should have an MRI (preferred) or CT each preferably with IV contrast of the brain prior to study entry.
  • •History of active primary immunodeficiency
  • •Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  • •Current or prior use of immunosuppressive medication within 14 days before the first dose of study drug. The following are exceptions to this criterion:
  • •Intranasal, inhaled, topical steroids, or local steroid injections (e.g. intra articular injection)
  • •Systemic corticosteroids at physiologic doses not to exceed 10 mg/ day of prednisone or its equivalent
  • •Steroids as premedication for hypersensitivity reactions (e.g. CT scan premedication)
  • •Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP.
  • •Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab
  • •+ oleclumab or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period
  • •Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
  • •Prior randomization or treatment in a previous durvalumab and/or oleclumab clinical study regardless of treatment arm assignment
  • •Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements

研究组 & 干预措施

Durvalumab

Experimental

-Durvalumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle

干预措施: Durvalumab (Drug)

Durvalumab + Oleclumab

Experimental
  • Durvalumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle
  • Oleclumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle

干预措施: Durvalumab (Drug)

Durvalumab + Oleclumab

Experimental
  • Durvalumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle
  • Oleclumab will be administered intravenously every 2 weeks, with 14 consecutive days defined as a treatment cycle

干预措施: Oleclumab (Drug)

结局指标

主要结局

Number of Participants Receiving at least One Dose of Study Therapy Followed by Surgery without Dose-Limiting Toxicity (DLT) up to Twelve Weeks Post-Radical Cystectomy (RC)

时间窗: 2 years

次要结局

  • Radiographic Progression by RECIST 1.1 Criteria from Time of Baseline Screening Imaging to the End of Treatment Imaging Pre-RC(2 years)
  • Number of Participants Receiving at least One Cycle of Study Therapy and Undergone RC Having <pT2N0 Disease at Time of RC(2 years)
  • Duration of Time of RC to Time of Documented Disease Relapse or Recurrence after RC(2 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Xiao X. Wei

Principal Investigator

Dana-Farber Cancer Institute

研究点 (2)

Loading locations...

相似试验

已完成
2 期
Durvalumab in HIV-1 Patients With Solid TumorsHIVCancer
NCT03094286Spanish Lung Cancer Group20
已完成
1 期
Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the LiverMetastatic Carcinoma in the LiverMLH1 Gene MutationMSH6 Gene MutationPMS2 Gene MutationStage IV Colorectal CancerStage IVA Colorectal CancerStage IVB Colorectal Cancer
NCT03005002City of Hope Medical Center9
已完成
2 期
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck CancerHead and Neck NeoplasmsMetastatic CancerHead and Neck Cancer
NCT03691714University of Cincinnati35
已完成
2 期
Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung CancerCarcinoma, Non-Small-Cell Lung
NCT02904954Weill Medical College of Cornell University60
已完成
2 期
A Study of Durvalumab With or Without Tremelimumab in Endometrial CancerEndometrial CancerEndometrial CarcinosarcomaEndometrial CarcinomaEndometrial Cancer RecurrentEndometrial Carcinoma, Recurrent
NCT03015129Memorial Sloan Kettering Cancer Center80